Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 410

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 410
---
Cs) and Antibody Drug Conjugates (ADCs) using DOR Technology

In addition to its innate immune agonist product candidates, we are using proprietary Delta Opioid Receptor (“DOR”) technology to develop small molecule or bi-specific/bifunctional immune modulating APCs and ADCs designed to inhibit the immune suppressing effects of tumor associated MDSCs on the tumor microenvironment (“TME”) to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors while modulating tumor ability to metastasize. Our DOR technology was developed by scientists at Moffitt Cancer Center and TuHURA Biopharma and was acquired in January 2023 when the company acquired the intellectual property assets of TuHURA Biopharma.

The tumor microenvironment, or TME, is the tissue surrounding a tumor, including the normal cells, blood vessels, and molecules that surround and feed a tumor cell and shield it from immune attack and eradication. MDSCs are a heterogeneous group of immature myeloid cells, which when recruited from the bone marrow to the TME, they transform to tumor-associated MDSCs which are characterized by their ability to suppress both**

<div align='center'>249</div>

**innate and adaptive immune responses. Tumor associated MDSCs are generally believed to be a major contributor to T cell exhaustion (which is the loss of ability of T cells to proliferate and to kill cancer cells) and for acquired resistance to checkpoint inhibitors and cellular therapies like T cell therapies. The presence of tumor associated MDSCs in the TME or circulating in the bloodstream is highly correlated with poor prognosis and outcome in a wide variety of solid tumors and blood related cancers.

We are developing peptidomimetic or small molecule DOR-selective inhibitors to incorporate into our bi-specific/bi-functional APCs and ADCs, which we believe represents a paradigm shift from conventional APCs or ADCs that are currently in development or being marketed. Traditional ADCs are a class of drugs in which a monoclonal antibody is chemically linked to a cancer-fighting substance. The antibody carries the cancer fighting payload to the tumor cell improving the selectivity of the resulting anti-cancer activity. like other APCs or ADCs, TuHURA’s APCs, and ADCs are designed to be bi-specific/ bi-functional,i.e., affecting two targets and having two functions: a bi-specific APC or ADC targets two distinct targets at the same time with two distinct molecules; peptidomimetic or small